Previous close | 2.6000 |
Open | 2.0000 |
Bid | 0.2000 |
Ask | 2.9000 |
Strike | 160.00 |
Expiry date | 2025-01-17 |
Day's range | 1.7000 - 2.0000 |
Contract range | N/A |
Volume | |
Open interest | 37 |
Biogen stock jumped Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?